Alcoholic Hepatitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Alcoholic Hepatitis – Pipeline Review, H2 2016’, provides an overview of the Alcoholic Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis

The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects

The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alfact Innovation

Conatus Pharmaceuticals Inc.

Generon (Shanghai) Corporation Ltd.

Genextra S.p.a.

Gilead Sciences, Inc.

GRI Bio, Inc.

Immuron Limited

Promethera Biosciences S.A.

Verlyx Pharma Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Alcoholic Hepatitis Overview 7

Therapeutics Development 8

Pipeline Products for Alcoholic Hepatitis - Overview 8

Pipeline Products for Alcoholic Hepatitis - Comparative Analysis 9

Alcoholic Hepatitis - Therapeutics under Development by Companies 10

Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes 11

Alcoholic Hepatitis - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Alcoholic Hepatitis - Products under Development by Companies 14

Alcoholic Hepatitis - Products under Investigation by Universities/Institutes 15

Alcoholic Hepatitis - Companies Involved in Therapeutics Development 16

Alfact Innovation 16

Conatus Pharmaceuticals Inc. 17

Generon (Shanghai) Corporation Ltd. 18

Genextra S.p.a. 19

Gilead Sciences, Inc. 20

GRI Bio, Inc. 21

Immuron Limited 22

Promethera Biosciences S.A. 23

Verlyx Pharma Inc. 24

Alcoholic Hepatitis - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

ALF-5755 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

emricasan - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

F-652 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

GRI-0621 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

HepaStem - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

IMM-124E - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

obeticholic acid - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

pentamidine isethionate - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

PMKM-02GI1 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

selonsertib - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Alcoholic Hepatitis - Dormant Projects 63

Alcoholic Hepatitis - Product Development Milestones 64

Featured News & Press Releases 64

Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 64

Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 64

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

List of Tables

Number of Products under Development for Alcoholic Hepatitis, H2 2016 8

Number of Products under Development for Alcoholic Hepatitis – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Alcoholic Hepatitis – Pipeline by Alfact Innovation, H2 2016 16

Alcoholic Hepatitis – Pipeline by Conatus Pharmaceuticals Inc., H2 2016 17

Alcoholic Hepatitis – Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 18

Alcoholic Hepatitis – Pipeline by Genextra S.p.a., H2 2016 19

Alcoholic Hepatitis – Pipeline by Gilead Sciences, Inc., H2 2016 20

Alcoholic Hepatitis – Pipeline by GRI Bio, Inc., H2 2016 21

Alcoholic Hepatitis – Pipeline by Immuron Limited, H2 2016 22

Alcoholic Hepatitis – Pipeline by Promethera Biosciences S.A., H2 2016 23

Alcoholic Hepatitis – Pipeline by Verlyx Pharma Inc., H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Alcoholic Hepatitis – Dormant Projects, H2 2016 63

List of Figures

List of Figures

Number of Products under Development for Alcoholic Hepatitis, H2 2016 8

Number of Products under Development for Alcoholic Hepatitis – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports